Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

被引：0
|
作者：
Strober, Bruce [1 ,2 ]
Paul, Carle [3 ]
Blauvelt, Andrew [4 ]
Thaci, Diamant [5 ]
Elewski, Boni [6 ]
White, Katy [7 ]
Vanvoorden, Veerle [7 ]
Deherder, Delphine [7 ]
Staelens, Fabienne [7 ]
Spelman, Lynda [8 ]
Eyerich, Kilian [9 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Cent Connecticut Dermatol Res, Cromwell, CT USA
[3] Paul Sabatier Univ, Toulouse, France
[4] Oregon Med Res Ctr, Portland, OR USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[7] UCB Pharma, Brussels, Belgium
[8] Verac Clin Res, Woolloongabba, Qld, Australia
[9] Tech Univ Munich, Munich, Germany
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [1] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
  • [2] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Lebwohl, Mark
    Ghoreschi, Kamran
    Strober, Bruce
    Eyerich, Kilian
    Cather, Jennifer
    Wang, Maggie
    Cioffi, Christopher
    Deherder, Delphine
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [3] Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48-144) of the BE RADIANT phase 3b trial
    Strober, Bruce
    Puig, Luis
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    Wang, Maggie
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Wiegratz, Susanne
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB21 - AB21
  • [4] Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48-144) of the BE RADIANT Phase 3b Trial
    Strober, Bruce
    Puig, Luis
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    Wang, Maggie
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Wiegratz, Susanne
    Merola, Joseph F.
    Paul, Carle
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2841 - 2844
  • [5] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [6] Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
    Warren, Richard B.
    Lebwohl, Mark
    Thaci, Diamant
    Gooderham, Melinda
    Pinter, Andreas
    Paul, Carle
    Gisondi, Paolo
    Szilagyi, Balint
    White, Katy
    Deherder, Delphine
    Staelens, Fabienne
    Lambert, Jeremy
    Strober, Bruce
    BRITISH JOURNAL OF DERMATOLOGY, 2025,
  • [7] Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
    Sinclair, Rodney
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Soung, Jennifer
    Strober, Bruce
    Wang, Maggie
    Cross, Nancy
    Deherder, Delphine
    Gomez, Natalie Nunez
    Gottlieb, Alice B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 18
  • [8] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Merola, Joseph F.
    Elewski, Boni
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
  • [9] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [10] Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
    Soung, Jennifer
    Rosmarin, David
    Ferrer, Anna Lopez
    Lain, Edward
    Rich, Phoebe
    White, Katy
    Staelens, Fabienne
    Szilagyi, Balint
    Deherder, Delphine
    Magnolo, Nina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB128 - AB128
12345